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To analyze MRI images in patients with MS who experienced worsening of neurologic status
(WNS) after stopping fingolimod (FTY).
Methods
In this retrospective study, demographic, clinical, and radiologic data of patients with MS who
experienced WNS after stopping FTY were retrospectively collected. We introduced the
“δExpanded Disability Status Scale (EDSS)-ratio” to identify patients who, after FTY with-
drawal, showed an inflammatory flare-up exceeding the highest lifetime disease activity level.
Patients with δEDSS-ratio > 1 were enrolled in the study.
Results
Eight patients were identified. The mean (SD) age of the 8 (7 female) patients was 35.3 (4.9)
years. The mean FTY treatment duration was 3.1 (0.8) years. The mean FTY
discontinuation–WNS interval was 4 (0.9) months. The 4 patients with δEDSS-ratio ≥ 2
developed severe monophasic WNS (EDSS score above 8.5), characterized by clinical features
and MRI findings not typical of MS, which we classified as “tumefactive demyelination pattern”
(TDL) and “Punctuated pattern” (PL). Conversely, patients whose δEDSS-ratio was between 1
and 2 had clinical features and brain MRI compatible with a more typical, even if aggressive, MS
relapse. In patients with TDL and PL, the flare-up of inflammatory activity led to severe tissue
damage resulting in T2 but also T1 lesion volume increase at 6-month follow-up.
Conclusions
Peculiar MRI features (TDL and PL), different from a typical MS flare-up, might occur in some
patients who experienced WNS after stopping FTY. Further studies, also involving immuno-
logic biomarkers, are necessary to investigate TDL or PL pathophysiology.
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Fingolimod (FTY) is an oral sphingosine-1-phosphate re-
ceptor (S1P1) modulator approved for MS. In the past few
years, worsening of neurologic status (WNS) has been de-
scribed in a small series of patients after FTY discontinua-
tion.1 This phenomenon remains controversial and regarded
as MS “reactivation”2 or considered a distinct “rebound”
phenomenon.3 Nevertheless, WNS after stopping FTY can
lead to severe disability or can even be life-threatening, and
thus the Food and Drug Administration recently issued
a warning on this topic.4 We report a retrospective series of 8
patients who developed WNS after FTY withdrawal focusing
on the different MRI patterns in the acute phase. The aim of
the study was to analyze MRI images in patients with MS who
experienced WNS after stopping FTY.
Methods
Standard protocol approvals, registrations,
and patient consent
A written informed consent was obtained from all patients.
Patients
From the systematic revision of clinical records of patients, we
collected clinical-radiological data of patients with MS who
developed WNS after FTY withdrawal between November
2013 and November 2017.
Clinical data analysis
We defined WNS by calculating the “post-FTY withdrawal
δExpanded Disability Status Scale (EDSS)/pre-FTY with-
drawal δEDSS ratio” (from now on called “δEDSS-ratio”),
where
1. post-FTY-withdrawal δEDSS is the highest EDSS score
change (δ) occurred after FTY withdrawal
2. pre-FTY-withdrawal δEDSS is the highest EDSS score
change (δ) occurred during the whole previous MS
course (i.e., worst lifetime relapse).
Patients with δEDSS-ratio > 1 were enrolled in the study.
WNS after FTY discontinuation was distinguished as mono-
phasic (one or more relapses, but with less than 1 month
between relapses), biphasic (2 relapses occurring at least 1
month apart), and multiphasic (≥3 relapses).
MRI acquisition and analysis
T2/FLAIR, TSE-T1 (before and after Gadolinium [Gd] ad-
ministration), and DWI, performed before FTY withdrawal,
during the WNS, and at 6-month follow-up (FU), were ana-
lyzed to obtain T2 and T1 lesion volume (LV), number and
pattern of Gd-enhancing lesions and volume of tissue with
restricted diffusion.
Data are reported as mean ± SD.
Data availability
Raw data are available upon appropriate request.
Results
We identified 8 patients. Seven patients were women. The
mean age was 35.3 ± 4.9 years. The mean duration of FTY
treatment was 3.1 ± 0.8 years. The most common cause of
FTY discontinuation was the attempt to become pregnant
(6 out of 7 female patients). The mean FTY discontinuation–
WNS interval was 4 ± 0.9 months.
We stratified patients according to the δEDSS ratio:
1. δEDSS-ratio ≥ 2 (Pt.1–Pt.4)
2. >1δEDSS-ratio < 2 (Pt.5–Pt.8).
Clinical features
The 4 patients with a δEDSS-ratio ≥ 2, developed a mono-
phasic WNS and reached EDSS scores of up to 9, 8.5 and 9.5
(Pt.1, Pt.3, and Pt.4); one patient (Pt.2) died. Pt.1, Pt.2, and
Pt.4 developed tetraplegia and multiple cranial nerve in-
volvement with decrease in consciousness rapidly resulting in
coma. Pt.3 presented a marked cognitive impairment associ-
ated with motor disability.
The 4 patients with δEDSS-ratio between 1 and 2, showed
multiphasic (Pt.5), biphasic (Pt.6 and Pt.7), and monophasic
(Pt.8) courses, characterized by multifocal neurologic deficits,
without altered state of consciousness.
At 2-year FU, for patients with δEDSS-ratio ≥ 2, disability
worsened when compared to patients with >1δEDSS-ratio < 2
(increase in mean EDSS points: 3 ± 2.9 vs 1.1 ± 1.2) (figure 1).
Demographic and clinical features and treatment performed
are detailed in the table.
MRI features
The 4 patients with a δEDSS-ratio ≥ 2 showed MRI features
that we defined as “tumefactive demyelination pattern” (TDL)
(Pt.2–Pt.4) and “punctuated pattern” (PL) (Pt.3) (figure 2,
figure e-1, links.lww.com/NXI/A109).
TDL was characterized by large T2/FLAIR hyperintense
lesions surrounded by marked edema, mass effect on adjacent
Glossary
CL = classic MS pattern; EDSS = expanded disability status scale; FTY = fingolimod; FU = follow-up; LV = lesion volume; PL =
punctuated pattern; TDL = tumefactive demyelination pattern; WNS = worsening of neurologic status.
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structures, and multiple enhancing lesions with an open ring
(40%), nodular (30%), or closed ring (30%) enhancement. A
large proportion of lesions had areas of restricted diffusion
(up to 30%) (figure 2). PL presented innumerable small T2/
FLAIR hyperintense lesions, mostly associated with contrast
enhancement and restricted diffusion (15%) (figure 2).
The 4 patients with the δEDSS-ratio between 1 and 2 showed
MRI features that we defined as “classic MS pattern” (figure 2,
figure e-1, links.lww.com/NXI/A109). Brain MRIs showed
T2/FLAIR lesions with no edema nor mass effect, some with
nodular/ring enhancement and only a small volume of tissue
with restricted diffusion.
At the 6-month FU, all patients exhibited a T2LV increase
compared to the pre-FTY suspensionMRI, although it decreased
according to the MRI scan at WNS, likely due to the partial
resolution of T2 hyperintensity. This finding was more evident
for patients with a δEDSS-ratio ≥ 2, particularly with TDL.
T1LV increased in all patients at the 6-month FU. Patients
who showed a higher volume of tissue characterized by re-
stricted diffusion at WNS had a higher T1LV % increase at
6-month FU (figure 1).
MRI data are detailed in the table.
Discussion
Severe WNS occurring in patients with MS after FTY with-
drawal is a rare and not completely understood phenomenon.
Although a recent post-hoc analysis of FREEDOMS-
FREEDOMS II trials found no difference in the development
of the so-called rebound between patients discontinuing FTY
and the placebo group,5 a small series reported increases in
clinical and radiologic disease activity after FTY cessation in
10.9%–25.8% of patients.1,6 Furthermore, a recent study con-
firmed that the “rebound” phenomenon after FTY suspension
does exist, with a risk estimated at 5%7 and recently FDA issued
a warning about severe MS worsening after stopping FTY.4 Cast
aside the controversy regarding the frequency, it is relevant to
consider that the “rebound” phenomenon leads to permanent
severe disability, may be life-threatening or even fatal, as occurred
to one patient of our cohort.
We retrospectively identified 8 patients who experienced,
after FTY withdrawal, a WNS exceeding the highest lifetime
level of MS activity, calculating the δEDSS-ratio to stratify
WNS severity. All patients were clinically stable during FTY
treatment, with 6 patients well enough to decide to plan
pregnancy.
Patients with δEDSS-ratio ≥ 2 developed severe monophasic
WNS (EDSS score above 8.5), characterized by clinical fea-
tures (i.e., tetraplegia resulting in coma) andMRI findings not
typical of MS. Large T2/FLAIR lesions with edema, ring/
nodular enhancement, and restricted diffusion characterized
TDL, while PL showed innumerable millimetric enhancing
lesions and a high rate of tissue with restricted diffusion.
Conversely, patients with >1δEDSS-ratio < 2 had clinical
features and brainMRI compatible with a more typical, even if
aggressive, MS relapse.
In patients with TDL and PL, the flare-up of inflammatory
activity led to severe tissue damage resulting in T2 but also
T1LV increase at 6 months; moreover, they demonstrated
larger areas of tissue with restricted diffusion, which may
Figure 1 EDSS score (A), T2LV (B) and T1LV (C) courses in
patients who experienced WNS after FTY
withdrawal
(A) EDSS scores were reported at FTY stop, WNS and 2-year follow-up.
Patients with δEDSS-ratio ≥ 2 reached very high EDSS scores at WNS and
accumulatedmore disability at 2-year follow-up when compared to patients
with >1 δEDSS-ratio >2. (B) T2LV was calculated at FTY stop, WNS and 6-
month FU. At the 6-month follow-up, all patients and particularly those with
δEDSS-ratio ≥ 2, had a T2LV increase compared to the pre-FTY suspension
MRI, although decreased with respect to the MRI scan at WNS, likely due to
the resolution of a portion of T2 hyperintensity, probably reflecting oedema.
(C) T1LVwas calculated at FTY stop and 6-month FU to consider chronic black
holes. At 6-month follow-up all patients, and particularly those with δEDSS-
ratio ≥ 2, showed a T1LV increase with respect to the MRI scan at WNS. EDSS =
expanded disability status scale; FTY = fingolimod; FU = follow-up; T1LV = T1
lesion volume; T2LV = T2 lesion volume; WNS = worsening of neurologic status;
δEDSS-ratio = post-FTY withdrawal δEDSS/pre-FTY withdrawal δEDSS ratio.
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Table Clinical and MRI features of patients with MS who experienced WNS after FTY withdrawal
Pt.1 Pt.2 Pt.3 Pt.4 Pt.5 Pt.6 Pt.7 Pt.8
Demographics
Sex F F F F F F F M
Age 40 26 35 33 30 33 39 46
Clinical data
MS type at withdrawal SPMS RRMS RRMS RRMS RRMS RRMS RRMS SPMS
MS duration at FTY stop
(y)
19 9 13 19 9 18 13 12
FTY duration (y) 4 2 4 3 3 3 3 4
Relapses and/or MRI
activity during FTY
No No No Yes No No No No
Cause of FTY withdrawal Progressive course Pregnancy attempt Pregnancy
attempt




FTY stop-WNS (m) 3 4 4 3 3 5 5 5

















NA 30 8 7 NA NA NA NA
























Spine involvement Yes No Yes Yes Yes No No No
EDSS at WNS 9 10 8.5 9.5 6.5 6.5 5.5 6
δEDSS ratio 2 3.5 3.2 2.1 1.8 1.2 1.2 1.5
WNS course Monophasic Monophasic Monophasic Monophasic Multiphasic Biphasic Biphasic Monophasic
WNS therapy CTS, PEX, AHSCT CTS, CYC CTS, PEX, RTX CTS, PEX, RTX CTS, ALEM CTS, AHSCT CTS, RTX CTS, NAT
FTY stop-2 y FU EDSS
increase
1 7 0.5 3.5 3 0.5 0.5 0.5
MRI data































Table Clinical and MRI features of patients with MS who experienced WNS after FTY withdrawal (continued)
Pt.1 Pt.2 Pt.3 Pt.4 Pt.5 Pt.6 Pt.7 Pt.8
T2 LVb (mL)
FTY stop 14 10 2 10 5 15 31 13
WNS 66 200 160 150 22c 34c 50c 25
6-mo FU 51 NA (exitus) 37 101 22 17 40 29
% Increase WNS-FTY
stop
264 1900 7,900 1,400 340c 126c 61c 92
% Increase 6 mo FU-
WNS
253 NA (exitus) 1750 910 340c 13c 29c 124
Gd + lesions at WNS (n) >50 >50 >50 35 3 (I), 3(II), 6(III)d 10 (I), 2(II)d 8 (I), 20 (II)d 6
Hypointense lesions at
WNS (ADC) (% of Gd
lesions)
Yes (≈15%)e Yes (≈25%)e Yes (≈30%)e Yes (15%) Yes (8%) Yes (2%) Yes (1%) Yes (1%)
LV restricted diffusionf
(mL)
2.4 4.2 5.8 2.8 0.6 0.3 0.3 0.1
T1 LVb (mL)
FTY stop 1 7 2 0.3 1 6 8 1
6-months FU 18 NA (exitus) 13 6 6 9 9 1.4
% Increase 6 month FU-
FTY stop
1700 NA (exitus) 550 1900 500 50 12 40
Abbreviations: ADC = apparent diffusion coefficient maps; AHSCT = autologous hematopoietic stem cells transplantation; ALEM = alemtuzumab; CL = Classic MS pattern; CTS = corticosteroids; CYC = cyclophosphamide; EDSS =
expanded disability status scale; FTY = fingolimod; FU = follow-up; LV = lesion volume; NA = not applicable; NAT = natalizumab; PEX = plasma exchange; PL = punctuated pattern; Pt = patient; RRMS, relapsing-remittingMS; RTX =
rituximab; SPMS, secondary progressive MS; T1LV = T1 lesion volume; T2LV = T2 lesion volume; TDL = tumefactive demyelinating pattern; WNS = worsening of neurologic status; δEDSS ratio = post-FTY withdrawal δEDSS/pre-
FTY withdrawal δEDSS ratio.
a For patients who experienced biphasic and multiphasic WNS, clinical features of each relapse are reported.
b Obtained by using a manual segmentation technique on 3-mm-slice thickness (Analyze, version 12.0).
c For Pt.5, Pt.6, and Pt.7, who experienced multiphasic and biphasic WNS, the highest T2LV was reported and used for the analysis.
d For Pt.5, Pt.6, and Pt.7, who experienced multiphasic and biphasic WNS, Gd enhancing lesions number of each relapse (I, II, III) was reported.
e For Pt.1, Pt.2, Pt.3, who had >50 Gd enhancing lesions, a maximum number of 50 Gd enhancing lesions was considered to calculate the rate of hypointense lesions on ADC maps.





























suggest that cytotoxic edema and/or high inflammatory cells
density within acute lesions resulted in more profound brain
tissue damage.8
The pathophysiology of the “rebound” phenomenon is still
unclear. Brain histologic examination of the patient who died
(reported in a separate publication) revealed prominent
astrocytic gliosis, with large hypertrophic reactive astrocytes
showing intense S1P1 expression.9 The role of astrocytes in
modulating the influx of leukocytes into the CNS has been
demonstrated in a model of experimental autoimmune en-
cephalitis10 and warrants further investigation in the context
of FTY withdrawal. MRI features similar to the TDL and PL
patterns that we described have been reported in patients with
evidence of B cell hyper-repopulation after alemtuzumab
treatment.11
The small size of our cohort represents a limitation of the
study. We used the δEDSS-ratio as a method to stratify the
patients who worsened after FTY suspension and its role as
a predictor of the outcome after WNS is unknown. In-
terestingly, patients with worse clinical course and outcome
were those who showed peculiar MRI features that we defined
TDL and PL, different from a typical MS flare-up. Further
studies are necessary to investigate whether specific cellular
subsets play a role in patients who develop a severeWNS after
FTY cessation.
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Figure 2 Brain MRI features of 3 representatives patients with MS who experienced WNS after FTY withdrawal
(A) Tumefactive demyelination pattern (TDL), Pt.3. (A.a) Axial T2/FLAIR images, showing large and edematous lesions, causing mass effect on adjacent
structures; (A.b) Axial TSE-T1 after Gd administration images, showing multiple ring and nodular enhancing lesions; (A.c) axial DWI (on the left) and
correspondent ADC maps (on the right) images, showing hyperintense lesions on DWI with correspondent hypointense signal on ADC maps (red arrows),
expression of restricted diffusion. (B) Punctuated pattern (PL), Pt.1, SPMS patient. (B.a) axial TSE-T2 images, medium in size (already detectable in previous
scans) and new small hyperintense lesions, with no edema andmass effect; (B.b) axial TSE-T1 after gadolinium administration images, showing innumerable
millimetric enhancing lesions, both in infratentorial and supratentorial areas. (B.c) axial DWI (on the left) and correspondent ADCmaps (on the right) images,
showing hyperintense lesions on DWI with correspondent hypointense signal on ADC maps (red arrows), expression of restricted diffusion. (C) Classic MS
pattern (CL). (Pt.6) (C.a) Axial FLAIR images, showingmedium in size lesions, with no edema andmass effect; (B.b) axial TSE-T1 after gadoliniumadministration
images, showing nodular and ring enhancing lesions. (C.c) Axial DWI (on the left) and correspondent ADC maps (on the right) images, showing hyperintense
lesions on DWI with correspondent hyperintense signal on ADC maps (“T2-shine through effect”).
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